These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Author: Li D, Chen JH, Wang J, Ling R, Yao Q, Wang L.
    Journal: Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556.
    Abstract:
    BACKGROUND & OBJECTIVE: Previous studies confirmed that fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging relates to clinical or pathologic responses of tumors to neoadjuvant therapy. This study was to evaluate the correlation of fused 18F-FDG PET/CT images to cell apoptosis of breast cancer after neoadjuvant chemotherapy, and explore its value in predicting the efficacy of neoadjuvant chemotherapy on breast cancer. METHODS: Forty-five patients with primary breast cancer, proven by core needle biopsy, underwent 3 cycles of neoadjuvant chemotherapy. PET/CT was performed before and after treatment, and the ratio of tumor area activity to non-tumor area activity (T/N) was calculated. The apoptosis index (AI) was determined using TUNEL technique. RESULTS: Of the 45 patients, 4(8.9%) achieved complete remission (CR), 29 (64.4%) achieved partial remission (PR), 10 (22.2%) presented stable disease (SD), and 2 (4.4%) presented progressive disease (PD) after neoadjuvant chemotherapy. The mean T/N ratio was decreased from 3.23+/-0.63 before chemotherapy to 2.31+/-0.49 after chemotherapy (P=0.006) by 6.4%-50.8%. The mean AI was increased from (2.81+/-0.76)% before chemotherapy to (17.31+/-6.85)% after chemotherapy (P<0.001) by 1.9%-41.3%. The T/N ratio reduction rate was positively correlated to AI change (r(s)=0.850, P<0.001). At a threshold of 20% decrease from baseline in T/N ratio, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT in predicting clinical response were 90.9%, 83.3%, 93.8%, 76.9%, and 92.1%, respectively. CONCLUSIONS: Neoadjuvant chemotherapy might effectively induce cell apoptosis in breast cancer and inhibit the glucose uptake. Fused PET/CT imaging is closely related to cell apoptosis status of breast cancer after neoadjuvant chemotherapy, and may be applied to predict the response of breast cancer to neoadjuvant chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]